Determination of frequency of spontaneous resistance for gepotidacin and levofloxacin against a collection of gram-positive and gram-negative organisms
Antimicrobial Agents and Chemotherapy · 03.06.2026 · 70 (6)
DOI: 10.1128/aac.01832-25 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 03.06.2026. Verfasst von Gina M Morgan und 7 weiteren Autor:innen. Beteiligte Einrichtung: JMI Laboratories/Element Materials Technology, North Liberty, Iowa, USA. Hauptthemen laut MEDLINE: Acenaphthenes, Anti-Bacterial Agents, Levofloxacin, Gram-Negative Bacteria. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 88 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: GlaxoSmithKline.
Abstract (Originalsprache)
Gepotidacin is a novel, bactericidal, first-in-class triazaacenaphthylene antimicrobial recently approved by the Food and Drug Administration (FDA) and Medicines and Healthcare products Regulatory Agency for the treatment of uncomplicated urinary tract infections (uUTI) and by the FDA for uncomplicated urogenital gonorrhea. Gepotidacin selectively inhibits type II topoisomerases involved in bacterial DNA replication by a distinct binding site and novel mechanism of action, conferring in vitro activity against most uropathogens, including those resistant to current antimicrobials. This study evaluated the potential of gepotidacin to select for spontaneous resistance in Citrobacter freundii , Enterobacter cloacae species complex, Klebsiella aerogenes , Klebsiella pneumoniae , Proteus mirabilis , Providencia rettgeri , Enterococcus faecalis , and Staphylococcus saprophyticus clinical isolates. Mutant frequencies ranged from 6.1 × 10 −8 to
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- JMI Laboratories/Element Materials Technology, North Liberty, Iowa, USA.
- GSK, Collegeville, Pennsylvania, USA.
ORCID-Profile: Gina M Morgan, John H Kimbrough, S J Ryan Arends, Nicole Scangarella-Oman
Förderung
- GlaxoSmithKline
Zitieren
APA
Morgan, G. M., Kimbrough, J. H., Karr, M. H., Thompson, J., West, J., Castanheira, M., Arends, S. J. R., & Scangarella-Oman, N. (2026). Determination of frequency of spontaneous resistance for gepotidacin and levofloxacin against a collection of gram-positive and gram-negative organisms. Antimicrobial Agents and Chemotherapy, 70(6). https://doi.org/10.1128/aac.01832-25
Vancouver
Morgan GM, Kimbrough JH, Karr MH, Thompson J, West J, Castanheira M, et al. Determination of frequency of spontaneous resistance for gepotidacin and levofloxacin against a collection of gram-positive and gram-negative organisms. Antimicrobial Agents and Chemotherapy. 2026;70(6). doi:10.1128/aac.01832-25
BibTeX
@article{Morgan2026,
author = {Morgan, Gina M and Kimbrough, John H and Karr, Maura H and Thompson, Jennifer and West, Josh and Castanheira, Mariana and Arends, S J Ryan and Scangarella-Oman, Nicole},
title = {Determination of frequency of spontaneous resistance for gepotidacin and levofloxacin against a collection of gram-positive and gram-negative organisms},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2026},
volume = {70},
number = {6},
doi = {10.1128/aac.01832-25}
}
EUVIMED